because of worsening HF as the primary cause of admission. The study hospitals were encouraged to register the patients as consecutively as possible. For each patient, baseline data included (1) demography; (2) cause of HF; (3) precipitating cause; (4) comorbidities; (5) complications; (6) clinical status; (7) electrocardiographic and echocardiographic findings; (8) plasma brain-type natriuretic peptide level; and (9) treatments, including discharge medications. Ischemic heart disease was defined as present if the patient had 1 of the following: (1) documented history of myocardial infarction, angina or prior coronary revascularization, (2) pathologic Q waves on ECG, (3) reversible defects on a thallium stress test, or (4) >75% stenosis in 1 or more coronary arteries on coronary angiograms. The data were entered using a web-based electronic data capture (EDC) system licensed by the JCARE-CARD (www.jcare-card.jp).
The JCARE-CARD enrolled a total of 2,675 patients hospitalized for HF at 164 participating hospitals from January 2004 to June 2005. Only patients who survived the initial hospitalization were included in the follow-up analysis. The diagnosis of AF was based on a 12-lead standard ECG performed at the time of inclusion in the study. Sixteen patients were excluded because of missing ECG data, resulting in 2,659 patients included in this analysis. They were divided into 2 groups according to the presence (n=937; 35.2%) or absence (n=1,722; 64.8%) of AF.
Outcomes
The status of all patients was surveyed on June 2006 at least 1 year after discharge and the following information was obtained from the participating cardiologists using the web-based EDC system: (1) survival, (2) cause of death, and (3) rehospitalization because of exacerbation of HF that required more than continuation of their usual therapy on prior admission. Follow-up data were obtained for 2,105 of the 2,659 patients (79.2%) and for 742 of the 937 AF patients (79.2%). Mean post-discharge follow up was 884± 255 days (2.4±0.6 years). Figure.
Kaplan-Meier event-free curves free from all-cause death (A), cardiac death (B), rehospitalization for worsening heart failure (C), and all-cause death or rehospitalization (D) comparing patients with atrial fibrillation (AF) (red lines) and without AF (black lines).
Statistical Analysis
Patient characteristics and treatments were compared using the Pearson chi-square test for categorical variables, Student's t-test for normally distributed continuous variables, and the Mann-Whitney U test for continuous variables not normally distributed. Cumulative event-free rates during follow-up were derived using the Kaplan-Meier method.
The relationship between the presence of AF at baseline and the outcome among patients was evaluated with multivariable adjustment. Baseline clinical variables, treatment factors, and the severity of HF at discharge were used in developing the post-discharge Cox proportional hazard models. A P value of <0.05 was used as the criterion for variables to stay in the model. SPSS version 16.0 J for Windows (Chicago, IL, USA) was used for all statistical analyses.
Results

Patient Characteristics
The present study included 2,659 patients with a mean age of 71.0±13.4 years and 59.8% men ( Table 1 ). The cause of HF was ischemic in 32.0%, valvular in 27.8%, hypertensive in 24.4%, and dilated cardiomyopathic in 18.2%. The mean left ventricular ejection fraction (LVEF) was 44.2± 16.5% at discharge. Patients with AF were significantly older and more often had valvular heart disease as the cause of HF, but less ischemic and hypertensive heart disease ( Table 1) . They were more likely to have had a prior stroke and hyperuricemia, but less often to have had hypertension, diabetes, hyperlipidemia, and a prior myocardial infarction. Their hemoglobin concentration was significantly higher and the LV end-diastolic diameters were smaller and LVEF greater than in the patients without AF.
Patients with AF were prescribed more often with diuretics, digitalis, and warfarin at discharge ( Table 2) . On the other hand, β-blockers, nitrates, antiarrhythmic, aspirin, antiplatelets, and statins were administered less in these patients.
Outcomes
During follow-up of 2.4 years after hospital discharge, the rates of adverse outcomes were as follows: all-cause death 21.2%, cardiac death 14.2%, rehospitalization because of worsening HF 35.5%, and all-cause death or rehospitalization 43.4%. These event rates were comparable between patients with and without AF (Figure) .
After adjustment for covariates, patients with AF had a comparable risk for all-cause death (adjusted hazard ratio The results of subgroup analysis for all-cause death stratified by sex, age (≥65 vs <65 years), etiology (ischemic vs non-ischemic, hypertensive vs no hypertensive, and valvular vs non-valvular heart disease), comorbidity (diabetes vs no diabetes and prior stroke vs no prior stroke), medication use (β-blocker vs no β-blocker use), and LVEF (<40% vs ≥40%) are shown in Table 3 . The finding on the primary analysis that the risk of adverse outcomes in patients with AF was not significantly different from those without AF was similarly found in each subgroup.
Of the patients with AF (n=937), 571 (60.9%) were treated with medications aimed at rate control, 129 (13.8%) were treated for rhythm control, and 192 (20.5%) had neither rate nor rhythm control therapy. Follow-up data were obtained in 497 of the 571 AF patients treated by rate control and in 111 of the 129 those treated by rhythm control. After adjustment for covariates, AF patients treated by rate or rhythm control had a comparable risk for allcause death (adjusted HR 0.713, 95%CI 0.319-1.593, P= 0.433), cardiac death (adjusted HR 0.591, 95%CI 0.206-1.697, P=0.329), rehospitalization because of worsening HF (adjusted HR 1.073, 95%CI 0.677-1.700, P=0.764), and all-cause death or rehospitalization (adjusted HR 0.933, 95%CI 0.598-1.455, P=0.759) ( Table 4) .
After adjustment for covariates, AF patients using warfarin had a significantly better outcome for all-cause death than those not using warfarin (adjusted HR 0.631, 95%CI 
Discussion
The present study used the JCARE-CARD database and found that AF was seen in 35% of patients hospitalized with HF. These patients more often had a valvular etiology for HF and greater LVEF. They were prescribed more digitalis and warfarin. Importantly, the risk of unadjusted, as well as adjusted adverse outcomes, including all-cause death, cardiac death, and rehospitalization because of worsening HF, was comparable between the AF and no-AF groups during long-term follow-up of 2.4 years. The present study results demonstrated that AF was not associated with adverse long-term outcomes in patients hospitalized with HF. However, the effect of AF on the mortality of HF patients is a controversial issue. Previous studies demonstrated that AF might be a prognostic factor in HF patients and this discrepancy might be associated with differences in the subjects and definitions of AF used among the studies. First, the present results consolidated previous studies conducted in selected patients as in the Veterans Affairs Vasodilator-Heart Failure Trial (V-HeFT) I and II, 3 the PRIME-II, 15 the Carvedilol or Metoprolol European Trial (COMET), 5 the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity Echocardiographic Substudy (CHARMES), 16 and reports from Pennsylvania 14 and France. 6 In the V-HeFT I and II studies, AF did not increase major morbidity or mortality of patients with mild to moderate HF. 3 Moreover, in the Prospective Randomized study of Ibopamine on Mortality and Efficacy (PRIME-II), the presence or development of AF in patients with severe HF was not independently related to adverse outcomes. 15 The Framingham Heart Study demonstrated that preexisting AF was not associated with adverse survival in subjects with HF. 11 On the other hand, in a retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trial, Dries et al reported that, after multivariate analysis, AF was significantly associated with all-cause mortality (adjusted HR 1.34, 95%CI 1.12-1.62, P=0.002), which could be largely related to progressive HF. 7 In the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial, both current and prior AF were associated with an increased risk of death and major cardiovascular events following acute myocardial infarction complicated by HF or LV dysfunction. 12 Similarly, the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) study reported that AF predicted a high risk of cardiovascular morbidity and mortality in patients with HF and either reduced or preserved LVEF. 13 Most of the previous data are from cohort studies and largescale clinical trials. Although several studies have shown a comparable risk of AF in patients with HF, they are recognized as unrepresentative of the general HF population encountered in clinical practice. Therefore, uncertainty pertaining to the applicability of these findings to the population of patients with HF at large persists. It is of critical importance to analyze registry data of enrolled HF patients without any exclusion criteria. Moreover, results might be influenced by differences in the cause of HF or the medical The Cox regression model used in the analysis adjusted for the following covariates: age, cause of heart failure (ischemic, hypertensive or valvular heart disease), medical history (diabetes, hyperlipidemia, hyperuricemia, prior stroke), serum creatinine, hemoglobin and BNP levels, LVEF, and medication use (diuretics, nitrates, aspirin, antiplatelet, warfarin, statin). AF patients treated for rate control were the reference group. BNP and LVEF at discharge were entered into the model as categorical variables; ie, BNP at discharge ≥240 pg/ml or <240 pg/ml or unknown and LVEF at discharge <40% or ≥40% or unknown. HR, hazard ratios. See Tables 1,3 for other abbreviations. The Cox regression model used in the analysis adjusted for the following covariates: age, cause of heart failure (ischemic, hypertensive or valvular heart disease), medical history (diabetes, hyperlipidemia, hyperuricemia, prior stroke), serum creatinine, hemoglobin, and BNP levels, LVEF, and medication use (β-blocker, diuretics, digitalis, nitrates, antiarrhythmic, aspirin, antiplatelets, statin). AF patients without warfarin use were the reference group. BNP and LVEF at discharge were entered into the model as categorical variables; ie, BNP at discharge ≥240 pg/ml or <240 pg/ml or unknown and LVEF at discharge <40% or ≥40% or unknown. See Tables 1,3,4 for abbreviations. care, including length of hospital stay and medication use, of Japanese patients compared with Western patients. For instance, in comparison with community-based studies of HF from the USA and Europe, Japanese cohort studies have demonstrated that mean age, prevalence of preserved EF, and trends in seasonal variation are comparable, but that the incidence of HF is obviously lower. 18 Therefore, it is of critical importance to analyze Japanese registry data enrolled HF patients. Previous Japanese cohort studies of HF patients have also reported that AF is not a significant risk factor for cardiac death. 19 The present results from the JCARE-CARD supported previous reports that AF is not associated with long-term adverse outcomes in Japanese HF patients. Second, the present study divided the study patients into AF and non-AF groups according to the baseline ECG findings, so patients with a history of AF, but who were in sinus rhythm at baseline, were categorized as non-AF. Moreover, the present study had no data regarding the new onset of AF. The Framingham Heart Study and the COMET showed that preexisting AF was not associated with adverse outcomes, whereas new onset AF was associated with increased mortality and morbidity in HF patients. 5, 11 New onset AF might cause more drastic deterioration of hemodynamics than preexisting AF, which could be attributable to the worsening of HF. However, PRIME-II demonstrated the opposite result that neither preexisting nor new onset AF was independently related to adverse outcomes during long-term follow-up in patients with advanced chronic HF. 15 Therefore, the effect of preexisting AF, as well as new onset AF, on the mortality of HF patients is still a controversial issue. AF is the 1 of the most important precipitating factors related to diastolic dysfunction. 16, 20 However, data on the prognostic effect of AF in patients with HF and preserved EF are conflicting. In the subgroup analysis of the present study, HF patients with LVEF ≥40% (n=523) also had a comparable risk between AF and no-AF for long-term adverse outcomes ( Table 3) . Our findings are consistent with those of CHARMES 16 and the report from France, 6 in which the risk of AF was comparable even in HF patients with preserved systolic function. However we are not in agreement with the findings of CHARM, 13 in which that the presence of AF was associated with a greater increase in the risk of cardiovascular events and mortality in the group with preserved EF (EF >40%) compared with reduced EF.
Current therapeutic options for HF patients with AF include rate or rhythm control to restore and maintain sinus rhythm. 21 The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trial could not demonstrate a significant difference in mortality between these 2 options in patients with AF after an average follow-up of 3.5 years. 22 In the Rate Control vs Electrical cardioversion for persistent atrial fibrillation (RACE) study, the incidence of hospitalization with HF was 3.5% with rate control and 4.5% with rhythm control. 23 Similarly, there were no differences in the composite endpoint (overall mortality, cerebrovascular complications, cardiopulmonary resuscitation, and embolic events) in the Strategies of Treatment of Atrial Fibrillation (STAF) trial 24 or in the composite endpoint (death, thromboembolic complications, and major hemorrhage) in the How to Treat Chronic Atrial Fibrillation (HOT CAFE) study. 25 In the Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial, rhythm control did not reduce the rate of death from cardiovascular causes, as compared with rate control, in patients with LVEF ≤35%. 26 Moreover, the present study demonstrated that AF patients treated for rate or rhythm control had a comparable risk for all-cause death, cardiac death, rehospitalization due to the worsening HF, and all-cause death or rehospitalization ( Table 4) .
In the present study, warfarin use reduced the rate of allcause death of AF patients. However, the rates of cardiac death, rehospitalization because of worsening HF, and death or rehospitalization were comparable between patients with and without warfarin use. These results were consistent with the prospective cohort study by Suzuki et al in which the lack of anticoagulation was an independent predictor for mortality in AF patients. 27 They might be due to the efficacy of warfarin in the prevention of embolic stroke especially in patients with AF.
Study Limitations
Several limitations inherent in the design of the JCARE-CARD should be considered. First, documentation of AF at baseline might not accurately reflect the persistent presence of AF after hospital discharge. Moreover, the present study did not obtain data regarding new onset AF during followup, which has been reported to have a prognostic effect in HF patients. 5, 11, 15 Thus in the present study we could not assess the effects of subsequent AF on the outcomes. Second, the JCARE-CARD is not a prospective randomized trial and, despite covariate adjustment, other measured and unmeasured factors might have influenced outcomes. We could not completely exclude other unmeasured factors that might also affect outcomes. Third, in the JCARE-CARD database, data of rhythm control therapy (eg, electrical cardioversion and catheter ablation) were not obtained, except for the use of antiarrhythmic drugs. Fourth, previous studies have demonstrated that the C-reactive protein (CRP) level is significantly higher in patients with AF than in those without AF and is associated with development of AF. 28, 29 However, in the JCARE-CARD database, data about systemic inflammatory markers such as CRP were not obtained. We thus could not assess the relation between inflammation and the outcomes of HF patients with and without AF in the present study. Finally, data were dependent on the accuracy of documentation and abstraction by the individual medical centers that participated in the program. A selection bias might exit in this study because the registration process was not strictly monitored. However, it was not the objective of this survey to restrict enrollment to the narrowly defined population of HF usually included in clinical trials, but rather to include a broad range of patients reflecting the current reality of clinical practice.
Conclusions
The present study demonstrated a higher prevalence of AF and no difference in the long-term outcomes of HF patients with and without AF in the "real world" of clinical practice in Japan.
